Clinical Trial

One-month Latent Tuberculosis Treatment for Renal Transplant Candidates

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a prospective, single-center, single-arm, open-label study investigating the safety, compliance and pharmacokinetics of 1-month treatment of Isoniazid, Rifapentine and Vitamin B6 in renal transplant candidates.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-06-06; most recent amendment 2026-01-16.
Status change: Recruiting → Active, Not Recruiting 2026-01-16
Status change: Not Yet Recruiting → Recruiting 2023-04-25
Trial Details
NCT Number NCT05411744
Lead Sponsor Rutgers, The State University of New Jersey
Conditions Latent Tuberculosis, End Stage Renal Disease, Renal Transplant Candidate for Right Kidney, Renal Transplant Candidate for Left Kidney
Enrollment 25 participants
Start Date 2022-07-01
Primary Completion 2026-01-16 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-21